摘要
目的探讨同步放化疗期间患者生活质量变化趋势,为改善患者治疗过程中的生活质量提供依据。方法本研究选取66例行同步放化疗的肺癌患者,采用欧洲癌症研究与治疗组织的肺癌患者生命质量测定量表(EORTC QLQ-C30)等,分析其治疗前、治疗结束时、治疗结束1月时的生活质量。结果患者治疗前、治疗结束时及治疗结束1月时的总体健康状况得分分别为73.11±22.40、51.22±26.05、67.80±18.19;配对t检验显示,治疗结束时与治疗前、治疗结束1月时的差异均有统计学意义(均P<0.01);各功能领域得分方面均表现为治疗前最高,治疗结束时最低,治疗结束1月时有所恢复,多数接近于治疗前水平。经配对t检验显示,患者的认知功能在3个时间段的得分差异无统计学意义(P>0.05);躯体功能方面3个时间段之间的差异有统计学意义(P<0.05);而角色功能、情绪功能及社会功能则仅在治疗结束时与治疗前之间的差异有统计学意义(P<0.05);患者在治疗前相关症状得分最高的是经济困难,其次为气短、失眠及疲乏;治疗结束时,相关症状的得分均有不同程度的提高;治疗结束1月时,相关症状的得分有所下降,但高于治疗前水平;经配对t检验显示,经济困难在3个时间段之间的差异均无统计学意义(均P>0.05);疲乏、疼痛及食欲缺乏在3个时间段之间的差异均有统计学意义(均P<0.05);失眠则仅在治疗前与治疗结束时的差异有统计学意义(P<0.05);气短则是治疗结束时与治疗前、治疗结束1月时的差异有统计学意义(P<0.05)。结论肺癌患者同步放化疗前的生活质量相对较好,同步放化疗后有所下降,但这种下降是暂时的、可逆的。
Objective To assess the quality of life in lung cancer patients undergoing concurrent chemoradiotherapy.Methods Sixty-six patients with lung cancer underwent concurrent chemoradiotherapy.The quality of life of patients was evaluated with EORTC QLQ-C30(Chinese version) before treatment(T0),at the end of treatment(T1) and one month after treatment(T2).Results The scores of overall quality of life(QOL) at T0,T1 and T2 were73.11 ± 22.40,51.22 ± 26.05 and 67.80 ± 18.19(P 〈 0.01),respectively.The scores of all functional dimensions decreased shortly at the end of concurrent chemoradiotherapy(T1),but increased one month after the treatment(T2),with most of them close to pre-treatment levels.The symptoms of fatigue,pain,insomnia,dyspnea and anorexia were worsened at T1(all P 〈 0.05) and improved at T2(all P 〈 0.05,except for insomnia) though still worse than those at T0(all P 〈0.05,except for insomnia and dyspnea).Conclusion The quality of life in lung cancer patients is relatively well before concurrent chemoradiotherapy,and chemo-radiation may induce a temporary and reversible decline in QOL.
出处
《实用肿瘤杂志》
CAS
2014年第6期560-563,共4页
Journal of Practical Oncology
关键词
肺肿瘤/放射疗法
肺肿瘤/药物疗法
配对分析
生活质量
治疗结果
随访研究
lung neoplasms/radiotherapy
lung neoplasms/drug therapy
matched-pair analysis
quality of life
treatment outcome
follow-up studies